Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05544448
Other study ID # APHP 220507
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 15, 2022
Est. completion date April 15, 2023

Study information

Verified date September 2022
Source Assistance Publique - Hôpitaux de Paris
Contact Philippe REMY, MD
Phone 01 49 81 24 59
Email Philippe.remy@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Interleukin 2 (IL-2) is a critical cytokine for the survival and function of regulatory T cells (LTreg). This cytokine has a dual role in the immune system. IL-2 stimulates immune responses by acting on the intermediate affinity IL-2R receptor, IL-2Rβγ, expressed by conventional T cells (LTconv) during activation, but also contributes to the inhibition of immune responses via LTreg that express the high affinity receptor IL-2Rαβγ. This difference in IL-2 receptor affinity for IL-2 has led to the development of low-dose IL-2 therapy to stimulate LTreg and improve control of excessive inflammation in autoimmune (AID), inflammatory or alloimmune diseases Low-dose IL-2 therapy is being studied in several of these diseases such as systemic lupus erythematosus, type 1 diabetes, alopecia, HCV (hepatitis C virus)-induced vasculitis, atopic dermatitis and chronic allo-transplantation-related graft-versus-host disease (GVHD). Some of these studies have shown an increase in LTreg numbers and an improvement in certain clinical signs. To improve LTreg targeting in autoimmune diseases, inflammatory diseases or GVHD, mutated IL-2s (muteins) have been developed with selective LTreg agonist properties. These IL-2 muteins are linked to an Fc fragment to increase their half-life. Two IL-2 variants (IL-2Vs)-Fc preferentially stimulate STAT5 phosphorylation in LTregs compared to conventional FoxP3- (LTconv) CD4+ or CD8+ T cells


Description:

Hypothesis: In order to confirm that this differential effect of IL-2 muteins, already established in non-diseased controls, is also observed in patients with autoimmune diseases, inflammatory diseases or GVHD, a pilot in vitro study should be conducted on a small number of patient's blood samples (5 or 10 depending on the pathology). Objective : Conduct a multicentre pilot study to confirm the hypothesis that IL-2 muteins preferentially activate the STAT5 pathway in LTreg compared to LTconv in patients with GVHD, acquired bone marrow aplasia, systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, autoimmune thyroiditis, vitiligo, alopecia or atopic dermatitis Method: At the inclusion, patients will have a blood sample collected for in vitro research purposes. Their clinical data will also be collected. Conclusion This trial should provide in vitro proof-of-principle of the efficacy of IL-2 muteins on LTreg and could eventually lead to a therapeutic trial


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 90
Est. completion date April 15, 2023
Est. primary completion date April 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Inclusion criteria common to all patients in different departments: - Age18 years - Affiliated to social security or entitled to - Patient who has been informed of the study and has signed a free and informed consent Inclusion criteria specific by department: Inclusion criteria for Clinical Hematology Department: - Patient with GVHD following allogeneic hematopoietic stem cell transplantation (HSC) - Or with acquired bone marrow suppression - Lymphocytosis > 0.5 G/L Inclusion criteria for Nephrology and Transplantation department: - Patient with systemic lupus erythematosus (ACR classification criteria) Inclusion criteria for Neurology department: - Patient with multiple sclerosis (criteria of Mc Donald 2017) Inclusion criteria for Rheumatology Department: - Patient with rheumatoid arthritis (ACR classification criteria) Inclusion criteria for Internal Medicine-Endocrinology Department: - Patient with Basedow disease, Hashimoto's thyroiditis Inclusion criteria for Dermatology Department: - Patient with vitiligo or alopecia areata or atopic dermatitis Exclusion Criteria: Non-inclusion criteria common to all patients: - Patient under guardianship, curatorship or judicial protection - Pregnant, parturient or breastfeeding woman - Patient deprived of liberty - Patient hospitalized without consent - Patient admitted to a health or social institution for purposes other than research - Minor patient - Adult patient unable to express consent - Refusal to participate - Patient on AME Non-inclusion criteria specific by department: Non-inclusion criteria for Clinical Hematology Department: - Ongoing treatment with high doses (>1 mg/kg/d) of systemic corticosteroid therapy - Ongoing treatment with JAK inhibitors Non-inclusion criteria for Nephrology and Transplantation Department: - Ongoing treatment with doses >10 mg/d Prednisone - Ongoing treatment with Cellcept, Endoxan, Imurel, Belimumab, Anti-CD20, Methotrexate - Ongoing treatment with JAK inhibitors Non-inclusion criteria for Neurology Department: - Treatment with systemic corticosteroid therapy, Fingolimod or Teriflunomide - Ongoing treatment with JAK inhibitors - Lymphocytosis < 0.5 G/L Non-inclusion criteria for Rheumatology Department: - Ongoing treatment with doses >15 mg/d Prednisone - Treatment with Rituximab or Tocilizumab - Ongoing treatment with JAK inhibitors - Lymphocytosis < 0.5 G/L Non-inclusion criteria for Internal Medicine - Endocrinology Department: - Ongoing immunosuppressive therapy - Ongoing treatment with JAK inhibitors Non-inclusion criteria for Dermatology Department: - Ongoing treatment with Methotrexate - Ongoing treatment with JAK inhibitors - Ongoing treatment with doses >10 mg/d prednisone

Study Design


Intervention

Other:
Blood sample taken at a single time point
At inclusion, a blood sample will be taken for research purpose

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Outcome

Type Measure Description Time frame Safety issue
Primary the percentage of phosphorylated STAT5 in LTresg compared to LTconv after incubation with IL-2 muteins The measurement method is based on the quantification of the phosphorylated STAT5 molecule in LTconv and LTreg by flow cytometry after incubating the cells with IL-2 or IL-2 muteins At inclusion
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4